The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.
<h4>Background</h4>Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test...
Guardado en:
Autores principales: | Jacob Fredsøe, Jan Koetsenruyter, Peter Vedsted, Pia Kirkegaard, Michael Væth, Adrian Edwards, Torben F Ørntoft, Karina D Sørensen, Flemming Bro |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/668685b9696f4e119afb9c3dbc46d199 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PSA journal
Publicado: (1947) -
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA
por: Julius Gudmundsson, et al.
Publicado: (2018) -
Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer
por: Samuel Carbunaru, et al.
Publicado: (2021) -
Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation
por: Navneeta Bansal, et al.
Publicado: (2017) -
Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
por: Maxine M Chen, et al.
Publicado: (2020)